Abstract:α-Synuclein (α-Syn), originally discovered in Alzheimer's disease brains (1), is one of the key molecules in neurodegenerative diseases, particularly in Parkinson's disease (PD) and dementia with Lewy bodies. Mitochondrial deficiency is another salient characteristic in the brain of patients with PD. Recently, a link between α-Syn and mitochondria in PD has been demonstrated; i.e., accumulation of α-Syn in the mitochondria from the PD-vulnerable brain regions was associated with decreased complex I activity of these mitochondria. In the current study, we quantitatively examined the expressions of α-Syn in mitochondria from different regions of normal rat brain. Wister rats (8 wk); isolation of mitochondria; quantification with Western blot analysis; NADH-CoQ oxidoreductase (complex I) activity; immuno-EM. We showed that α-Syn was highly expressed in the mitochondria in olfactory bulb, hippocampus, striatum, and thalamus, where the cytosolic α-Syn was also rich. However, the cerebral cortex and cerebellum were two exceptions; these regions contained rich cytosolic α-Syn but very low or undetectable levels of mitochondrial α-Syn. Quantitatively, there was a close association between mitochondrial α-Syn and cytosolic α-Syn in most brain regions, suggesting that the concentration of cytosolic α-Syn may determine the amount of α-Syn in mitochondria. This is supported, in part, by an in vitro experiment where the incubation of recombinant α-Syn with endogenous α-Syn-undetectable mitochondria from cerebellum caused a dose-dependent transport of α-Syn into the mitochondria. Moreover, we found that the inhibitory effect of α-Syn on complex I activity of mitochondrial respiratory chain was also dose-dependent. These results suggest that in normal brain mitochondrial α-Syn is differentially expressed in different brain regions and the background levels of mitochondrial α-Syn may be a potential factor affecting mitochondrial function predisposing some neurons to degeneration in diseased brains.

Increased Oligomerization and Phosphorylation of Α-Synuclein Are Associated with Decreased Activity of Glucocerebrosidase and Protein Phosphatase 2A in Aging Monkey Brains

Mutant Alpha-Synuclein Causes Age-Dependent Neuropathology in Monkey Brain

Age-dependent Aggregation of Α-Synuclein in the Nervous System of Gut-Brain Axis is Associated with Caspase-1 Activation.

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

Enzymatic O-GlcNAcylation of Α-Synuclein Reduces Aggregation and Increases SDS-resistant Soluble Oligomers

Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age

Non-Motor Parkinsonian Pathology In Aging A53t Alpha-Synuclein Mice Is Associated With Progressive Synucleinopathy And Altered Enzymatic Function

Glial senescence enhances α-synuclein pathology owing to its insufficient clearance caused by autophagy dysfunction

Analysis of Α-Synuclein Species Enriched from Cerebral Cortex of Humans with Sporadic Dementia with Lewy Bodies.

Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesis

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

P4‐195: Mitochondrial Alpha‐synuclein: Implications in Neurodegenerative Diseases

Molecular Signatures of Neurodegenerative Diseases Identified by Proteomic and Phosphoproteomic Analyses in Aging Mouse Brain

Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinson’s Disease Models

Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia

Quantitative proteomic profiling of the rat substantia nigra places glial fibrillary acidic protein at the hub of proteins dysregulated during aging: Implications for idiopathic Parkinson's disease

Α‐synuclein Stimulation of Monoamine Oxidase‐b and Legumain Protease Mediates the Pathology of Parkinson's Disease

Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein

Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease

Impairment of Mitochondria in Adult Mouse Brain Overexpressing Predominantly Full-Length, N-Terminally Acetylated Human α-Synuclein

1 serine 129 phosphorylation reduces α-synuclein ’ s ability to regulate tyrosine hydroxylase and protein phosphatase 2 a in vitro and in vivo